85 4 CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | PART TWO Supplementary materials Table S1. Treatment groups DEX arm MCP arm PALO arm OND DEX OND DEX MET PALO DEX Day 1 8 mg IV 8 mg IV 8 mg IV 8 mg IV 0.25 mg IV 8 mg IV Day 2 8 mg PO 30 mg PO Day 3 8 mg PO 30 mg PO OND, DEX and PALO were administered 30 min prior to chemotherapy on day 1. On days 2-3, DEX was administered 4 mg PO two times a day. On days 2-3, MET was administered 10 mg PO three times a day. Abbreviations: DEX, dexamethasone; IV, intravenously; MET, metoclopramide; OND, ondansetron; PALO, palonosetron; PO, orally Table S2. Patient baseline and disease characteristics (intention-to-treat population). All patients (n = 230) DEX arm (n = 77) MCP arm (n = 79) PAL arm (n = 74) Age (years) Median (range) ≤55 years >55 years 66.0 (40-84) 33 (14.3) 197 (85.6) 64.0 (46-82) 11 (14.3) 66 (85.7) 67.0 (40-84) 14 (17.7) 65 (82.3) 67.5 (40-83)) 8 (10.8) 66 (89.2) Gender Male Female 128 (55.7) 102 (44.3) 42 (54.5) 35 (45.5) 44 (55.7) 35 (44.3) 42 (56.8) 32 (43.2) Tumor type Colorectal Ovarian Lung Gastric Pancreatic Other 196 14 7 6 5 2 66 5 1 2 3 0 65 5 5 2 1 1 65 4 1 2 1 1 Chemotherapy Oxaliplatin-baseda Carboplatin-basedb Irinotecan -based Antracycline-basedc Other 188 21 14 6 1 64 6 5 2 0 62 10 5 2 0 62 5 4 2 1 Abbreviations: DEX, 3-day dexamethasone; MCP, metoclopramide; PAL, palonosetron aOxaliplatin dose: 130 mg/m2 bCarboplatin dose: area under the curve (AUC) ≥4 mg/mL/minute (reclassified as highly emetogenic) cEpirubicin dose: 50 mg/m2 All data are N (%) unless otherwise indicated.
RkJQdWJsaXNoZXIy MjY0ODMw